Polyrizon Ltd. PLRZ
Polyrizon Ltd. (Nasdaq: PLRZ) is a respiratory medical device company. Its next catalyst on record is PL-16: FDA pre-submission meeting (IDE study type and De Novo pathway) (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: PL-16 — FDA pre-submission meeting (IDE study type and De Novo pathway) (H2 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| T&T intranasal drug-delivery platform (nasal delivery of APIs, e.g. corticosteroids, benzodiazepines, naloxone) | Intranasal delivery of APIs | small molecule | Pre-clinical |
| NASARIX allergy blocker (planned 510(k), Class II) | Allergic rhinitis symptoms | device-combination | NA_NON_THERAPEUTIC |
| PL-16 (virus blocker nasal spray; Pre-RFD submitted December 2025; De Novo pathway contemplated) | Barrier against respiratory viruses (influenza, COVID-19) | device-combination | NA_NON_THERAPEUTIC |
Recent results and decisions
- Jun 29, 2026n/a Central IRB (BRANY) approved protocol for first human trial of NASARIX versus saline in seasonal allergic rhinitis; site activation pending.
This approval from BRANY Institutional Review Board (granted June 18, 2026) is a key regulatory milestone for the Company.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.